Several therapeutic antibodies targeting protein–protein interactions have been approved for use in the clinic, including pembrolizumab directed against the well-known PD-1 protein for the treatment of cancer [131] and adalimumab that specifically binds to the tumor necrosis factor (TNF)-α and used for the treatment of autoimmune diseases [132,133]. Here, TNF is linked to autoimmune disease.